UK biotech Synairgen saw the value of its shares crater after its inhaled interferon beta therapy SNG001 was found to provide no benefit to people hospitalised with COVID-19. The drug – originally ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback